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72 The Journal of Thoracic and Cardiobjective: The specific effect of protein kinase C, the primary ventricular calcium-
ependent protein kinase C isoform, on myocardial protection is unclear. The
bjective of this study was to determine the role of protein kinase C in myocardial
rotection and recovery of function after cardioplegic arrest, cold preservation, and
ormothermic reperfusion, as relevant to cardiac transplantation.
ethods: We used an ex vivo murine model, and hearts were arrested with cold
rystalloid cardioplegia or saline as a control and maintained at 4°C for 4 hours.
his was followed by normothermic reperfusion for 90 minutes. Transgenic hearts
ith cardiac-specific activation or inhibition of protein kinase C were then studied
o specifically examine the effects of protein kinase C on myocardial preservation
n this model.
esults: Cardioplegic arrest with University of Wisconsin solution led to signifi-
antly improved postreperfusion hemodynamics and inhibition of myocardial pro-
ein kinase C activity relative to that seen in saline-treated control hearts. -Ad-
energic receptor signaling was also preserved with University of Wisconsin
olution. Transgenic hearts with enhanced protein kinase C activity had poor
ostreperfusion hemodynamics, impaired -adrenergic receptor signaling, and in-
reased G protein–coupled receptor kinase 2 activity compared with those seen in
ontransgenic control hearts. In contrast, transgenic hearts with inhibited protein
inase C activity had even better myocardial protection relative to control hearts
nd preserved -adrenergic receptor signaling.
onclusions: Current techniques of myocardial preservation are associated with
nhibition of protein kinase C activity and maintenance of intact -adrenergic
eceptor signaling. Activation of protein kinase C leads to enhanced -adrenergic
eceptor desensitization and impaired signaling and ventricular function as a result
f increased G protein–coupled receptor kinase 2 activity. This is a novel in vivo
echanism of G protein–coupled receptor kinase 2 activation. Strategies to specif-
cally inhibit these kinases might improve long-term myocardial protection.
 
he protein kinase C (PKC) family of serine–threonine kinases func
downstream of several membrane-associated signal transduction path-
ways.E1 There are approximately 10 different isozymes that make up
KC family, and they are broadly classified by their activation characteristics. The
onventional PKC isozymes (, I, II, and ) are Ca2 and lipid activated,
hereas the novel isozymes (, , , and ) and the atypical isozymes ( and 	) are
a2 independent but activated by distinct lipids.E2 PKC is the predominan
a2-dependent PKC isoform expressed in murine and human hearts.E3
Several reports have associated PKC activation with hypertrophy, dilated car-
iomyopathy, ischemic injury, and mitogen stimulation.E1 There is also som
vidence implicating PKC isozymes as potential regulators of Ca2 handling and
vascular Surgery ● January 2008
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TXardiomyocyte contractility. Stimulation of PKC activity by
horbol ester has been shown to decrease cardiac contrac-
ility in isolated rat hearts and isolated cultured cells, and
his effect was abrogated with PKC inhibitors.E4,E5 Previous
tudies have also shown that PKC functions as a funda-
ental regulator of cardiac contractility and Ca2 handling
n myocytes.E6,E7 For example, PKC gene-deleted mice
ere shown to be hypercontractile, whereas transgenic mice
verexpressing PKC were hypocontractile.
The effects of cardioplegic arrest and hypothermic pres-
rvation on myocardial PKC activity have not been spe-
ifically investigated, and that is the primary objective of
his study. We used an ex vivo murine model of cardiople-
ic arrest, followed by cold preservation and subsequent
ormothermic reperfusion as relevant to heart transplanta-
ion, to determine whether PKC activity might be an
mportant factor in myocardial protection in this setting. In
ddition, a novel in vivo mechanism by which PKC can
egulate myocardial -adrenergic receptor (AR) signaling
nd ventricular function was investigated.
aterials and Methods
ll animals received humane care in compliance with the “Prin-
iples of laboratory animal care” formulated by the National
ociety for Medical Research and the “Guide for the care and use
f laboratory animals” prepared by the National Academy of
ciences and published by the National Institutes of Health. All
xperimental protocols were approved by the Institutional Animal
are and Use Committee of the University of Cincinnati.
x Vivo Cardiac Physiology
he mice used in this study were 3 months of age, and all were
ale. All mice in this study were of the FVB/n background. The
ice were anesthetized intraperitoneally with pentobarbital solu-
ion. After thoracotomy, the hearts were rapidly excised and placed
n a Langendorff apparatus. The hearts were perfused in a retro-
rade aortic fashion at a constant mean pressure of 50 mm Hg with
rebs–Henseleit bicarbonate buffer solution (118 mmol/L NaCl,
.7 mmol/L KCl.2, 25 mmol/L MgSO4, 1.2 mmol/L KH2PO4, 2.5
mol/L CaCl2, and 11 mmol/L glucose, pH 7.4) at 37°C and
quilibrated with a mixture of 95% oxygen and 5% carbon dioxide
as. The preload was also held constant at a perfusate flow rate of
Abbreviations and Acronyms
ACT  specific activation
ATP  Adenosine triphosphate
AR  -Adrenergic receptor
CK  creatine kinase
GRK G protein–coupled receptor kinase
INH  specific inhibition
PKC  protein kinase C
UW  University of WisconsinmL/min. During the stabilization period, a polyethylene catheter p
The Journal of Thoracic-50 was inserted into the left ventricle through the left atrium and
onnected to a pressure transducer. The left ventricular pressure
ignals were digitized at 1 kHz and analyzed by using the com-
uter software Biobench (National Instruments). The first positive
nd negative derivatives of the left intraventricular pressure curve
dP/dt and –dP/dt) and the duration of contraction and relaxation
time to peak pressure) and time to half relaxation were calculated.
acing was used to maintain a heart rate of 400 beats/min in all
tudies.
esearch Design
ll hearts were perfused for 30 minutes to achieve stable hemo-
ynamics. This was followed by antegrade delivery of 3 mL of
old University of Wisconsin (UW) preservation solution or 3 mL
f cold saline in the control group. After arrest, hearts were stored
n UW solution at 4°C for 4 hours. The cold preservation period
as then followed by 90 minutes of normothermic reperfusion
ith loading conditions identical to the initial basal period of
erfusion. After hemodynamic measurements, all hearts were
nap-frozen in liquid nitrogen for later preparation for biochemical
tudies.
ransgenic Mice
he transgenic mice used in this study have been previously
escribed.E7 There is an approximately 1.5-fold increase in m-
ardial PKC activity driven by cardiac-specific expression of a
pecific receptor for activated C kinase peptide using the -myosin
eavy chain promoter. The transgenic animals at 3 months of age
howed no differences in cardiac morphology or histology com-
ared with the nontransgenic control animals, and baseline systolic
nd diastolic cardiac function was also not different from that seen
n control animals.E7 The transgenic mice with cardiac-specifi
nhibition of PKC activity showed a 25% decrease in PKC
ctivity compared with that seen in nontransgenic control
nimals.E7
xperimental Groups
n the first set of experiments, the 2 groups consisted of hearts
eceiving 3 mL of cold UW solution (cardioplegia [CP] group) and
earts receiving 3 mL of cold saline (SA group) before hypother-
ic preservation in UW solution. The second set of experiments
nvolved comparing transgenic hearts with activation or inhibition
f PKC with nontransgenic control hearts to further delineate the
ffects of this PKC isoform on myocardial function after car-
ioplegic arrest and preservation.
reatine Kinase Activity
n assay kit (Sigma) was used to quantitate total creatine kinase
CK) activity in 1 mL of myocardial perfusion effluent at the end
f the reperfusion period to determine the degree of cardiac myo-
yte damage.
rotein Immunoblotting
fter the perfusion protocol, atrial tissue was removed, and the
entricles were snap-frozen in liquid nitrogen. Ventricles were
hen homogenized with a Polytron (Brinkman) at 10,000 rpm in
ce-cold lysis buffer, including protease inhibitors. PKC isoform
artitioning in subcellular fractions was assayed in cytosolic
and Cardiovascular Surgery ● Volume 135, Number 1 173
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1
TX100,000g supernatant) and Triton X-100–extracted membrane
100,000g pellet) ventricular fractions. Sixty micrograms of pro-
ein for each cytosolic and membrane sample was electrophoresed
hrough 12% Tris–glycine gels and then transferred to nitrocellu-
ose membranes. The membranes were blocked for 1 hour in 5%
onfat milk and probed with commercially available primary poly-
lonal antibodies to PKC, , and  isoforms (Santa Cruz Bio-
echnology). The membranes were then washed in TBS-Tween
olution and incubated with a goat anti-rabbit secondary antibody,
ollowed by exposure to an ECL (Amersham) reagent. Densitom-
try was performed with a FluorChem 8800 with AlphaEaseFC
luorChem 8900 software (Alpha Innotech Corp).
easurement of G Protein–coupled Receptor Kinase
ctivity
he membrane fractions of the myocardial extracts were used to
etermine G protein–coupled receptor kinase (GRK) activity. Ex-
racts (100 
g of protein) were incubated with rhodopsin-enriched
od outer-segment membranes in reaction buffer containing the
ollowing: MgCl2, 10 mmol/L; Tris-HCl, 20 mmol/L; ethylenedi-
mine tetraacetic acid, 2 mmol/L; ethyleneglycol-bis(-aminoeth-
lether)-N,N,N=,N=-tetraacetic acid, 5 mmol/L; and adenosine
riphosphate (ATP), 0.1 mmol/L (containing [-32P]ATP). After
ncubating in white light for 15 minutes at room temperature,
eactions were quenched with ice-cold lysis buffer and centrifuged
or 15 minutes at 13,000g. Sedimented proteins were resuspended
n 25 
L of protein gel loading dye and treated with 12% SDS-
AGE. Phosphorylated rhodopsin was visualized by means of
utoradiography of dried polyacrylamide gels and quantified by
sing a Molecular Dynamics PhosphorImager.
adioligand Binding Assays
otal AR density was determined by incubating 25 
g of cardiac
arcolemmal membranes with a saturating concentration of iodine
25–labeled cyanopindolol and 20 
mol/L alprenolol to define
onspecific binding. Sarcolemmal membrane samples were stud-
ed in triplicate with 80 pmol/L iodine 125–labeled cyanopindolol
nd 104 mol/L isoproterenol in 250 
L of binding buffer (50
mol/L HEPES [pH 7.3], 5 mmol/L MgCl2, and 0.1 mmol/L
scorbic acid). Assays were performed at 37°C for 1 hour and then
ltered over GF/C glass fiber filters (Whatman) that were washed
wice and counted in a gamma counter. Data were analyzed by
sing the nonlinear least-square curve fit (GraphPad Prism).
arcolemmal Membrane Adenylyl Cyclase Activity
ardiac sarcolemmal membranes (20 
g of protein) were incu-
ated for 15 minutes at 37°C with (-32P)ATP under basal condi-
ions, 104 mol/L isoproterenol, or 10 mmol/L NaF. Cyclic aden-
sine monophosphate production was quantified by using standard
ethods described previously.E8
tatistical Analysis
esults are presented as means  standard error of the mean
SEM). Experimental groups were compared by using the Student
test or 1-way analysis of variance, as appropriate. The Bonferroni
est was applied to all significant analysis of variance results by
sing SigmaStat software. p
74 The Journal of Thoracic and Cardiovascular Surgery ● Januesults
yocardial Functional Recovery
hese studies were performed in nontransgenic mice to
nvestigate the effects of cardioplegic arrest and hypother-
ic preservation on myocardial function and to establish the
rotective effect of UW solution in this murine model.
earts were treated with antegrade perfusion of 3 mL of
aline (control, SA group) or 3 mL of UW preservation
olution (CP group) after 30 minutes of baseline normother-
ic perfusion. Baseline systolic and diastolic cardiac func-
ion were identical between experimental groups (Table
he control (SA) group hearts, which received 3 mL of cold
aline followed by hypothermic storage for 4 hours at 4°C
nd normothermic reperfusion for 90 minutes, recovered
nly 31% of basal dP/dtmax and 32% of basal dP/dtmin. In
ddition, left ventricular end-diastolic pressure was mark-
dly increased to 59.5 13.1 mm Hg from a baseline of 9.2
 3.3 mm Hg (Table 1). The CP group, in contrast, in 
earts were arrested with 3 mL of UW solution followed by
hours of hypothermic storage and 90 minutes of normo-
hermic reperfusion, showed recovery of dP/dtmax to 81% of
aseline and dP/dtmin to 77% of baseline. Left ventricular
nd-diastolic pressure after ischemia and reperfusion in the
P group was also much lower compared with that seen in
he control group at 18.6  4.2 mm Hg (Table 1). Heart r
uring basal conditions and after the experimental protocol
as not different between groups because external pacing
as used to maintain a heart rate of 400 beats/min. CK
ctivity was measured in the effluent from the perfusion
ystem at the end of the reperfusion period to assess myo-
yte damage after cold preservation and normothermic
eperfusion. The total CK activity was nearly 2.5-fold
reater in the control hearts compared with that seen in the
P group (Figure 1). The hemodynamic data and the d
f myocyte injury demonstrated that this was a valid murine
odel of cardioplegic arrest and cold preservation because
here was a highly significant difference in myocardial
ABLE 1. Hemodynamic measurements of left ventricular
unction before and after cold preservation and normother-
ic reperfusion
Baseline
Control
(saline) Cardioplegia
dP/dtmax (mm Hg/s) 3626 274 1116  174 2937  424*
ecovery (%) 31 81*
dP/dtmin (mm Hg/s) 3611 209 1108  74 2781  447*
ecovery (%) 32 77*
VEDP (mm Hg) 9.2 3.3 59.5 13.1 18.6  4.2*
R (beats/min) 400 1 400  2 400  2
 9 in each group. All hearts were paced. LVEDP, Left ventricular
nd-diastolic pressure; HR, heart rate. *P  .05 versus control.reservation with UW solution versus hypothermia alone.
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TXW solution is very commonly used for preservation of
onor hearts in the clinical setting.
ssessment of PKC Activity
yocardial PKC isoform activity was studied in both
roups after 4 hours of cold preservation and 90 minutes of
ormothermic reperfusion. The ratio of PKC isoform ex-
ression in the membrane fraction to the cytosolic fraction
s an indirect measure of kinase activity because it translo-
ates from the cytosolic fraction to the membrane fraction,
here it phosphorylates other signaling molecules and
embrane proteins. In the saline control group there was a
-fold increase in myocardial PKC activity relative to that
een in the CP group (Figure 2). The PKC isoform has
een shown to play an important role in myocardial recov-
ry after normothermic ischemia-reperfusion injury.E1
here was no significant difference in PKC activity be-
ween groups at the end of the cold preservation and reper-
usion period in our model (Figure 3). These results 
nstrate that inhibition of PKC might be an important
echanism of cardioplegia-mediated myocardial protection
rom ischemia-reperfusion injury.
ffects on AR Signaling
ecause the AR signaling system is critical in the regula-
ion of cardiac contractility and can be modulated by PKC,
his pathway was investigated before and after cardioplegic
rrest, cold preservation, and normothermic reperfusion
ith this model. Total myocardial sarcolemmal membrane
AR density was not different before or after the preserva-
ion period in both the SA and CP groups (Table 2).
igure 1. Creatine kinase activity in 1 mL of myocardial effluent
fter 90 minutes of normothermic reperfusion. *P < .01 versus
ontrol (SA group); n  9 in each group.asal and isoproterenol-stimulated adenylyl cyclase activity c
The Journal of Thoracic-
th
as significantly lower in the SA group after reperfusion
ompared with that seen in the CP group (Table 2). Cy
ctivity stimulated by NaF was not different between
roups, indicating preservation of G protein–adenylyl cy-
lase coupling. These data also indicate that the defect in
AR signaling involves uncoupling of these receptors from
heir downstream effector, adenylyl cyclase. Activity of
igure 2. Myocardial PKC activity after cardioplegic arrest,
old preservation, and normothermic reperfusion. M, Membrane
raction; C, cytosolic fraction; CP, cardioplegia (University of
isconsin) solution. *P< .05 versus control; n  9 in each group.
109kDa
78kDa
 Control CP
PKCε (80kD)
C M  C M
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
M
/C
?
ra
ti
o
Control CP
igure 3. Myocardial PKC activity after cardioplegic arrest, cold
reservation, and normothermic reperfusion. M, Membrane frac-
ion; C, cytosolic fraction; CP, cardioplegia (University of Wis-
onsin) solution. *P < .05 versus control; n  7 in each group.
and Cardiovascular Surgery ● Volume 135, Number 1 175
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1
TXRK2, a member of the family of serine–threonine kinases
nown as G protein–coupled receptor kinases, which phos-
horylates and desensitizes agonist-occupied ARs, was
ignificantly increased after reperfusion in the SA group
ompared with that in the CP group (Figure 4). There
o difference in GRK2 activity between groups at baseline.
hese results suggest that AR desensitization plays an
mportant role in myocardial dysfunction in the SA group
nd might be associated with activation of PKC.
unctional Consequences of Myocardial PKC
ctivation and Inhibition
ecause PKC is the predominant Ca2-dependent PKC
soform in the murine heart and activity of this isoform was
ignificantly inhibited by cardioplegic arrest with UW so-
ution, we studied cardiac function after cardioplegic arrest,
ABLE 2. Myocardial -adrenergic receptor signaling
AR density, fmol/mg membrane protein (baseline)
AR density, fmol/mg membrane protein (after reperfusion)
asal AC activity, pmol cAMP · mg1 · min1 (baseline)
SO AC activity, pmol cAMP · mg1 · min1 (baseline)
asal AC activity, pmol cAMP · mg1 · min1 (after reperfusion)
SO AC activity, pmol cAMP · mg1 · min1 (after reperfusion)
 8 in each group. AR, -Adrenergic receptor density; AC, adenylyl c
04 mol/L isoproterenol. *P  .05 versus CP group.
0
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    SA SA      CP      CP
       (baseline)      (post - reperfusion)    (baseline)   (post - reperfusion)
*
 *
Baseline     Post-reperfusion
Rho (~38kDa)
SA     CP   CP   CP  SA SA
igure 4. G protein– coupled receptor kinase (GRK2) activity be-
ore and after cold preservation and normothermic reperfusion.
A, Saline; CP, cardioplegia (University of Wisconsin) solution.(P < .001 versus control (SA group); n  8 in each group.
76 The Journal of Thoracic and Cardiovascular Surgery ● Janus
old preservation, and normothermic reperfusion in trans-
enic hearts with specific activation (PKC ACT) or inhibi-
ion (PKC INH) of PKC and also compared these values
ith those seen in nontransgenic control hearts. These stud-
es with transgenic mice might more specifically delineate
he effects of PKC on cardiac function after preservation
nd reperfusion. The transgenic mice used in this study had
modest 1.5-fold cardiac-specific increase in PKC activity
PKC ACT) or a 25% decrease in myocardial PKC activity
PKC INH) relative to that seen in control mice.E7 Baseline
ardiac function was similar between the transgenic and
ontransgenic hearts (Table 3). After CP arrest, cold p
rvation, and the warm reperfusion period, there was a
ighly significant difference in functional recovery because
KC activation led to severely impaired myocardial re-
overy of both systolic function (1822  111 vs 2918 
07 mm Hg/s, P  .01) and diastolic function (1518  125
s 2601  118 mm Hg/s, P  .05) compared with baseline
alues, which were not different between groups (Table
n contrast, inhibition of PKC activity led to significantly
etter recovery of myocardial systolic function (3499 188
s 2918  107 mm Hg/s, P  .01) and diastolic function
3214  145 vs 2601  118 mm Hg/s, P  .01) after
reservation and reperfusion compared with that seen in the
ontransgenic hearts (Table 3). The transgenic hearts w
rrested with cold saline followed by hypothermic storage
nd normothermic reperfusion (n  10 in each group) to
urther evaluate the significance of PKC activity on myo-
ardial protection. The PKC ACT hearts treated with saline
ecovered only 14% of baseline dP/dtmax and 12% of
aseline dP/dtmin. In contrast, the PKC INH group treated
ith saline recovered 62% of baseline dP/dtmax and 58%
f baselinedP/dtmin (P .01 vs PKC ACT). The recovery
f left ventricular systolic and diastolic function in the
aline-treated PKC ACT hearts was also significantly worse
han that in the saline-treated nontransgenic hearts (P 
05), and the PKC INH hearts treated with saline had sig-
ificantly improved recovery (approximately 2-fold) rela-
ive to that of the nontransgenic group arrested with saline
Saline-treated group Cardioplegia-treated group
62.5 5.8 67.2 7.4
65.9 7.1 64.0 4.9
45.8 6.4 52.1 8.3
103.6 18.3 110.7 14.9
21.2 5.7* 45.5 9.2
32.8 6.6* 106.1 18.5
e activity; cAMP, cyclic adenosine monophosphate; ISO, stimulation withyclasP  .01).
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TXyocardial GRK2 Activity and -adrenergic Signaling
n Transgenic Mice
otal myocardial AR density was not different between
KC ACT and PKC INH hearts under basal conditions or
fter cold preservation and reperfusion (Table 4). In 
rast, basal and isoproterenol-stimulated adenylyl cyclase
ctivity in myocardial sarcolemmal membranes was signif-
cantly lower in the PKC ACT mice at baseline and after
old preservation and reperfusion (Table 4). These 
ndicate that activation of PKC is associated with AR
esensitization as cyclase activity is inhibited. To determine
potential mechanism, we measured myocardial GRK2
ctivity using rhodopsin phosphorylation. GRK2 activity
as greater in the PKC ACT hearts compared with that seen
n the PKC INH and nontransgenic control hearts both
efore and after the preservation and reperfusion period
Figure 5, A). In contrast, there was no difference betw
roups in myocardial GRK2 protein expression either be-
ore or after hypothermic preservation and reperfusion (
re 5, B). It appears that activation of PKC can lead to
ctivation of GRK2 in vivo and that the resulting AR
esensitization or receptor-effector uncoupling might rep-
esent an important mechanism of myocardial dysfunction
fter cardiac preservation.
iscussion
yocardial protection in cardiac surgery has continued to
mprove and has led to better outcomes after elective oper-
ABLE 3. Hemodynamic measurements of left ventricular
eperfusion
Control
aseline dP/dtmax (mm Hg/s) 3741
ostreperfusion dP/dtmax (mm Hg/s) 2918
ecovery (%) 78
aseline dP/dtmin (mm Hg/s) 3467
ostreperfusion dP/dtmin (mm Hg/s) 2601
ecovery (%) 75
eart rate (beats/min) 400
 11 in each group. All hearts were paced. *P .05 versus control and P
inase C; ACT, specific activation; INH, specific inhibition.
ABLE 4. Myocardial -adrenergic receptor signaling in t
AR density, fmol/mg membrane protein (baseline)
AR density (after reperfusion)
asal AC activity, pmol cAMP · mg1 · min1 (baseline)
SO AC activity, pmol cAMP · mg1 · min1 (baseline)
asal AC activity, pmol cAMP · mg1 · min1 (after reperfusion)
SO AC activity, pmol cAMP · mg1 · min1 (after reperfusion)
 8 in each group. PKC, Protein kinase C; ACT, specific activation; INH
ctivity; cAMP, cyclic adenosine monophosphate; ISO, stimulation with 104 m
The Journal of Thoracictions, as well as cardiac transplantation. Previous studies
ave described the improvements in myocardial metabolic
unction with cardioplegic arrest and hypothermia, and
hese have been the foundation of current cardioplegia so-
utions, as well as organ-preservation solutions, such as UW
olution.E9 Pharmacologic strategies to minimize tissue a-
dosis and cellular hypercalcemia and to preserve high-
nergy phosphates have been quite effective.E10-E12 Unfor-
unately, there has been very little progress in cardiac donor
rgan-preservation strategies to further increase the safe
uration of ischemia, which might provide a greater number
f available donor organs. In addition, much of the early
yocardial dysfunction that is occasionally present after
llograft reperfusion might be minimized with more effec-
ive means of myocardial protection.
PKC has been implicated as a critical signaling mol-
cule in mediating cardiac functional recovery after
schemia-reperfusion injury and particularly in mediating
schemic preconditioning.E13-E15 PKC was first describe
s a phospholipid-dependent serine–threonine kinase that
s activated as a result of receptor-dependent activation of
hospholipase C and the hydrolysis of membrane phos-
hoinositides.E16 Activation of PKC isoforms involv
ranslocation from the cytosolic fraction of cells to the
embrane or particulate fraction. PKC has been shown to
hosphorylate ARs in vitro and can also phosphorylate
articular contractile proteins, such as troponin I.E17 The
tion before and after cold preservation and normothermic
PKC ACT PKC INH
3795 142 3804 202
1822 111* 3499 188†
48* 92†
3613 163 3694 184
1518 125* 3214 145†
42* 87†
400 1 400  3
H. †P .05 versus PKC ACT and control. Ntg, Nontransgenic; PKC, protein
genic mice
PKC ACT PKC INH
56.9 3.8 60.2  6.9
55.2 6.1 56.8  5.0
40.8 5.3 45.9  6.3
87.4 15.5* 125.2  17.1
23.9 4.2* 44.8  7.4
42.0 6.9* 118.4  15.9
cific inhibition; AR, -adrenergic receptor density; AC, adenylyl cyclasefunc
Ntg
291
107
147
118
3
KC INrans
, spe
ol/L isoproterenol. *P  0.05 versus PKC INH.
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1
TXKC family of ubiquitous serine–threonine kinases now
umbers 12 distinct isoforms.E8 Cardiac myocytes coex-
ress multiple PKC isoforms, and there is general con-
ensus that ventricular myocytes coexpress calcium-sen-
itive PKC, novel PKC and PKC, and atypical
igure 5. A, G protein– coupled receptor kinase (GRK2) activity in
ransgenic protein kinase C (PKC)  hearts with specific inhibi-
ion (INH) and PKC hearts with specific activation (ACT) before
nd after cold preservation and normothermic reperfusion. B,
aseline; P, after reperfusion; NTg, nontransgenic. *P < .001
ersus NTg control and PKC INH hearts; n  8 in each group. B,
otal myocardial GRK2 protein expression. There was no differ-
nce between groups. B, Baseline; P, after reperfusion; NTg,
ontransgenic. N  8 in each group.KC	 . E18 Prior studies have shown that the PKC iso- a
78 The Journal of Thoracic and Cardiovascular Surgery ● Januorm represents nearly 80% of total PKC expression in
he rat and murine heartE7,E19 and is an important isofor
n the human heart.E3,E20
Our data show that cardioplegic arrest inhibits activation
f PKC. This was associated with significantly better
entricular function after normothermic reperfusion and
uch less myocyte damage, as measured by CK release. In
ddition, activation of PKC was also associated with im-
aired AR signaling, as assessed on the basis of myocar-
ial sarcolemmal membrane adenylyl cyclase activity.
RK2 activity was increased with resultant AR desensi-
ization. Previous studies have shown that PKC can phos-
horylate and activate GRK2 in vitro.E21,E22 Isoform-spe-
ific studies have not been performed, however, with regard
o activation of GRK2. PKC has been shown to have
mportant effects on cardiac function in vivo. Cardiac-
pecific PKC overexpression in transgenic mice resulted in
 blunting of basal and -agonist–stimulated contractility.E6
echanistically, modulation of PKC activity affects de-
hosphorylation of the sarcoplasmic reticulum Ca2 AT-
ase 2 pump inhibitory protein phospholamban and alters
arcoplasmic reticulum Ca2 loading and the Ca2 tran-
ient. PKC was found to directly phosphorylate protein
hosphatase inhibitor 1, altering the activity of protein
hosphatase 1, which might account for the effects of PKC
n phospholamban phosphorylation and blunted contractil-
ty.E6 In contrast, homozygous deletion of PKC in gene-
argeted mice led to enhanced basal and -agonist–stimu-
ated contractility.E6
To determine the effects of PKC activation on myo-
ardial preservation and recovery after cardioplegic ar-
est in a more specific fashion, we used transgenic mice
ith cardiac-specific activation (PKC ACT) or inhibition
PKC INH) of PKC activity. PKC activation resulted
rom overexpression of a specific receptor for activated C
inase, which is critical in the targeted translocation of
KC from the cytosolic to the membrane fraction of
ardiac myocytes.E7 As previously described, this lea
o a modest 1.5-fold increase in myocardial PKC ac-
ivity.E7 The transgenic mice with cardiac-specific in-
ition of PKC activity showed a 25% decrease in PKC
ctivity compared with that seen in nontransgenic control
nimals through expression of an inhibitory peptideE7
he PKC ACT hearts had significantly worse recovery of
oth systolic and diastolic left ventricular function com-
ared with the nontransgenic control hearts. In contrast,
KC INH hearts had even greater recovery of left ven-
ricular function after cardioplegic arrest and reperfusion
ersus the nontransgenic hearts. It appears that inhibition
f PKC activity is an important mechanism in myocar-
ial protection and preservation with cardioplegic arrest.
Our data also demonstrate, for the first time, that PKC
ctivation can lead to enhanced GRK2 activity and AR
ary 2008
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D’Souza et al Cardiothoracic Transplantationesensitization in vivo and, more specifically, in the heart.
his might represent another important mechanism by
hich PKC can alter myocardial function. Impaired car-
iac AR signaling and increased GRK2 activity are clas-
ical characteristics of chronic heart failure in human sub-
ects and experimental animal models.E23,E24 Activation of
KC isoforms in cardiac hypertrophy might lead to en-
anced GRK2 activity and contribute to AR desensitiza-
ion in the transition from compensatory hypertrophy to
eart failure.
Recently, it has been reported that gene therapy–based
nhibition of PKC/ enhances cardiac contractility and atten-
ates heart failure in a rat model of postinfarction cardiomy-
pathy.E25 This report clearly demonstrates the important -
ect of PKC as a negative regulator of cardiac contractility c
The Journal of Thoracicnd shows the potentially beneficial effect of inhibiting this
KC isoform on cardiac function after myocardial injury. Our
ata also show that even modest inhibition of PKC activity
as dramatic effects on left ventricular recovery in a model of
ardioplegic arrest and hypothermic preservation followed by
ormothermic reperfusion. This appears to be an important
echanism by which UW solution provides myocardial pro-
ection. It is possible that the development of specific pharma-
ologic inhibitors of PKC might further improve current
echniques of cardiac preservation in the setting of cardiac
urgery and particularly in cardiac transplantation, where organ
reservation remains very limited. In addition, novel ap-
roaches to inhibit GRK2-mediated AR desensitization
ight represent another potential opportunity to improve myo-ardial protection.
and Cardiovascular Surgery ● Volume 135, Number 1 179
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